Scarica l'app Stockscreener
71.71
2.22%
-1.63
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Halozyme Therapeutics, Inc. $HALO Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 - AOL.com
What Halozyme Therapeutics (HALO)'s Upgraded Revenue Outlook and ENHANZE Acquisitions Strategy Means For Shareholders - Yahoo Finance
AlphaQuest LLC Acquires 34,011 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Setup Watch: Is Halozyme Therapeutics Inc forming a breakout patternDip Buying & AI Optimized Trading Strategy Guides - baoquankhu1.vn
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Q4 EPS Forecast for Halozyme Therapeutics Lifted by Analyst - MarketBeat
Great Lakes Advisors LLC Sells 14,747 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating - Finviz
H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating - Yahoo Finance
Halozyme stock price target maintained at $58 by Goldman Sachs - Investing.com Canada
HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance - Yahoo Finance
Halozyme Acquires Surf Bio for up to $400M - Contract Pharma
H.C. Wainwright reiterates Buy rating on Halozyme stock, maintains $90 price target - Investing.com Canada
Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2026 Earnings Guidance - MarketBeat
Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth and Technical Setup - Chartmill
Federated Hermes Inc. Has $106.40 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Is Halozyme Therapeutics (HALO) Offering Value After Strong Multi‑Year Share Price Gains - Yahoo Finance
Halozyme Therapeutics Projects Sustained Growth Well Into 2040 - Benzinga
Risk Off: What is Halozyme Therapeutics Incs market position2025 Breakouts & Breakdowns & Consistent Return Strategy Ideas - baoquankhu1.vn
Halozyme Deepens ENHANZE Reach With Surf Bio Deal And Takeda Tie-Up - Yahoo Finance
Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s - MarketBeat
Halozyme buys a biotech startup; Cytokinetics launches heart drug - BioPharma Dive
Halozyme Therapeutics Raises 2025, 2026 Outlooks - marketscreener.com
(HALO) Halozyme Therapeutics Expects Full Year 2026 Non-GAAP EPS Range $7.75$8.25, vs. FactSet Est of $8.24 - marketscreener.com
Halozyme Therapeutics, Inc. acquired Surf Bio, Inc. for $400 million. - marketscreener.com
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance - The Malaysian Reserve
Halozyme (HALO) Projects Strong Revenue Growth for FY26 - GuruFocus
Halozyme Therapeutics, Inc. Raises Earnings Guidance for the Year 2026 - marketscreener.com
Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Year Ended December 31, 2025 - marketscreener.com
Enhanced Guidance Boosts Halozyme's (HALO) Growth Prospects - GuruFocus
Halozyme Lifts 2025 Revenue Outlook, FY26 Guidance - Nasdaq
Halozyme raises 2025 revenue estimates, raises 2026 and multi-year financial guidance - marketscreener.com
Hussman Strategic Advisors Inc. Reduces Stock Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
EFG Asset Management North America Corp. Has $5.83 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
How Takeda ENHANZE License Deal in IBD Will Impact Halozyme Therapeutics (HALO) Investors - Sahm
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Exploring a 11.42% Potential Upside with Strong Revenue Growth - DirectorsTalk Interviews
Biotech Recovery: Halozyme and Catalyst Stocks Surge Amid Strong Growth - Intellectia AI
Halozyme and Catalyst Report Double-Digit Revenue Growth, Strong Outlook - Intellectia AI
Value Recap: Will Halozyme Therapeutics Inc benefit from rate cutsJuly 2025 Earnings & Free Community Supported Trade Ideas - baoquankhu1.vn
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance - Insider Monkey
Can Halozyme Therapeutics Inc benefit from deglobalizationWeekly Market Report & Target Return Focused Picks - baoquankhu1.vn
How (HALO) Movements Inform Risk Allocation Models - Stock Traders Daily
14 Best Mid-Cap Growth Stocks to Buy Right Now - Insider Monkey
Reframing The Narrative For Halozyme Therapeutics (HALO) After The Latest Analyst Price Target - Yahoo Finance
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update - The Malaysian Reserve
Assessing Halozyme Therapeutics (HALO) Valuation After Recent Share Price Consolidation - Yahoo Finance
Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade - Insider Monkey
Skye Bioscience shares rise on Halozyme partnership to advance obesity treatment - MSN
Halozyme Takeda ENHANZE Deal Links Growth Potential With Valuation Upside - Sahm
Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty - The Globe and Mail
Is Takeda ENHANZE Deal on Vedolizumab Reshaping the Investment Case for Halozyme Therapeutics (HALO)? - Sahm
1.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):